Medtronic has announced the first commercial use of its Liberant thrombectomy system, which is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems. Medtronic notes that Liberant expands the company’s portfolio of treatment options for peripheral arterial and venous diseases to include mechanical aspiration thrombectomy.
The first procedure using the Liberant thrombectomy system was performed by vascular surgeon Ajit Rao, MD, a vascular surgeon at The Mount Sinai Hospital in New York City. on Nov. 21. “The Liberant thrombectomy system is an effective new tool that performs well even in complex cases, maneuvering through challenging anatomy with ease and limiting blood loss through an intelligent algorithm,” said Rao. “We’re able to remove clot burden with greater precision and, for patients, this means a procedure designed to be more efficient and aimed at helping them restore circulation and mobility as safely and effectively as possible.”
A press release notes that the Liberant platform leverages an intelligent algorithm that automatically adapts the pulse rate to provide appropriate aspiration power and pairs it with key advancements in catheter technology and blood conservation.
Medtronic shares that the launch of Liberant is the first milestone in a series of broader investments in peripheral and venous thrombectomy solutions by the company. This includes pipeline investments as well as the initiation of a multicenter, real-world clinical assessment to evaluate the periprocedural device performance of both Liberant and the Excipio thrombectomy system.
The company advises that Liberant and Excipio have Food and Drug Administration (FDA) clearance and are currently available in the U.S.
